866-997-4948(US-Canada Toll Free)

Global Co-promotion and Co-marketing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2015

Published By :

Current Partnering

Published Date : Dec 2015

Category :

Advertising and Marketing

No. of Pages : 792 Pages

The Global Co-promotion and Co-marketing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2015 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading healthcare companies.

Revised and updated 12th edition, includes:

  • Trends in co-promotion and co-marketing deals
  • Co-promotion and co-marketing agreement structure
  • Co-promotion and co-marketing contract documents
  • Top co-promotion deals by value
  • Top co-marketing deals by value
  • Most active co-promotion dealmakers
  • Most active co-marketing dealmakers

This report provides details of the latest co-promotion and co-marketing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors.

Fully revised and updated, the report provides details of co-promotion and co-marketing agreements from 2010 to mid 2015.

The report provides a detailed understanding and analysis of how and why companies enter co-promotion and co-marketing deals. The majority of deals are multicomponent whereby the licensor retains either a right or option to co-promote/market the resultant product of the research collaboration. There are also numerous pure co-promotion/marketing deals whereby the products originator takes on a co-promotion/marketing partner in order to maximize a products presence in the marketplace.

The report provides a detailed understand and analysis of how and why companies enter co-promotion and co-marketing deals. The majority of deals are multicomponent whereby the licensor retains either a right or option to co-promote/market the resultant product of the research collaboration. There are also numerous pure co-promotion/marketing deals whereby the products originator takes on a co-promotion/marketing partner in order to maximize a products presence in the marketplace.

Understanding the flexibility of a prospective partner

Table of Content

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in co-promotion and co-marketing dealmaking

2.1. Introduction
2.2. Difference between co-promotion and co-marketing deals
2.3. Trends in co-promotion deals since 2010
2.4. Trends in co-marketing deals since 2010
2.4.1. When co-marketing can be useful
2.4.2. When co-marketing is the only option
2.5. Pure deals and multi-component deals
2.5.1. Attributes of pure co-promotion deals
2.5.2. Attributes of co-promotion in multi-component deals
2.6. Reasons for including co-promotion options in a deal
2.7. Uptake of co-promotion rights
2.8. Co-promotion rights as bargaining chips
2.9. Aligning partners to make the co-promote work
2.10 The future of co-promotion as part of multicomponent deals

Chapter 3 – Overview of co-promotion deal structure
3.1. Introduction
3.2. Pure versus multi-component co-promotion deals
3.3. Pure co-promotion agreement structure
3.3.1. Example co-promotion agreements
3.3.1.a. Case study 1: Allergan – MAP Pharmaceuticals – January 2011
3.3.1.b. Case study 2: Genzyme – Veracyte – January 2012
3.4. Co-promotion rights as part of a wider alliance agreement
3.4.1. Example co-promotion option clauses
3.4.1.a. Case study 3: Takeda Pharmaceutical– Orexigen Therapeutics– Sep 2010
3.4.1.b. Case study 4: Celgene – Acceleron Pharma– Aug 2011
3.4.2. Example co-promotion right clauses
3.4.2.a. Case study 5: Takeda – Orexigen – September 2010
3.4.2.b. Case study 6: Abbvie – Receptos – March 2013
3.5. Embedded co-promotion rights enabling third party engagement
3.5.1. Example co-promotion clauses enabling third party engagement
3.5.1.a. Case study 7: Astellas – Ambit Biosciences – December 2009

Chapter 4 – Overview of co-marketing deal structure
4.1. Introduction
4.2. Co-marketing agreement structure
4.2.1. Example co-marketing agreements
4.2.1.a. Case study 8: AstraZeneca –Ironwood Pharmaceuticals– Oct 2012
4.3. Co-marketing rights as part of a wider alliance agreement
4.3.1. Example co-marketing right clauses
4.3.1.a. Case study 9: Lundbeck – Myriad Genetics – May 2008

Chapter 5 – Leading co-promotion deals
5.1. Introduction
5.2. Top co-promotion deals by value
5.3. Most active co-promotion dealmakers
5.4. Big pharma co-promotion deal activity
5.5. Big biotech co-promotion deal activity

Chapter 6 – Leading co-marketing deals
6.1. Introduction
6.2. Top co-marketing deals by value
6.3. Most active co-marketing dealmakers
6.4. Big pharma co-marketing deal activity

Chapter 7 – Big pharma co-promotion and co-marketing deals
7.1. Introduction
7.2. How to use co-promotion and co-marketing deals
7.3. Big pharma co-promotion and co-marketing agreement listings

Chapter 8 – Co-promotion agreement contracts directory 2010-2015
8.1. Introduction
8.2. Co-promotion partnering deals by company A-Z
8.3. Co-promotion partnering deals by therapy area
8.4. Co-promotion partnering deals by stage of development at signing
8.5. Co-promotion partnering deals by technology area

Chapter 9 – Co-marketing agreement contracts directory 2010-2015
9.1. Introduction
9.2. Co-marketing partnering deals by company A-Z
9.3. Co-marketing partnering deals by therapy area
9.4. Co-marketing partnering deals by stage of development at signing
9.5. Co-marketing partnering deals by technology type

About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering

 

List of Table

NA

List of Chart

Figure 1: Definition of co-promotion and co-marketing
Figure 2: Trends in co-promotion deal announcements, 2010-2015
Figure 3: Co-promotion deals signed at each phase of development, 2010-2015
Figure 4: Trends in co-marketing deal announcements, 2010-2015
Figure 5: Co-marketing deals signed at certain phases of development, 2010-2015
Figure 6: Situations where co-marketing can prove useful
Figure 7: Pure versus multi-component co-promotion deal announcements, 2010-2015
Figure 8: Stage of development at which pure and multi-component co-promotion deals are announced 2002-2015
Figure 9: Pure versus multi-component co-marketing deal announcements, 2010-2015
Figure 10: Stage of development at which pure and multi-component co-marketing deals are announced 2002-2015
Figure 11: Key components of a pure co-promotion deal
Figure 12: Key components of a multi-component co-promotion deal
Figure 13: Example deals where co-promotion options have been actively exercised, since 2000
Figure 14: Issues in implementing co-promotion agreements
Figure 15: Co-promotion agreements – what should a contract include?
Figure 16: Components of the co-promotion deal structure
Figure 17: Components of the co-marketing deal structure
Figure 18: Top co-promotion deals by value since 2010
Figure 19: Most active co-promotion dealmakers 2010-2015
Figure 20: Big pharma – top 50 – co-promotion deals 2010 to 2015
Figure 21: Big pharma co-promotion deal frequency - 2010 to 2015
Figure 22: Big biotech – top 50 – co-promotion deals 2010 to 2015
Figure 23: Big biotech co-promotion deal frequency - 2010 to 2015
Figure 24: Top co-marketing deals by value since 2010
Figure 25: Most active co-marketing dealmakers 2010-2015
Figure 26: Big pharma – top 50 – co-marketing deals 2010 to 2015
Figure 27: Big pharma co-marketing deal frequency - 2010 to 2015

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *